Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| COAG | PRESS-RELEASE | neutral | 5/10 | Hemab Therapeutics reported a Q1 2026 net loss of $22.7M ($23.98/share), widening from a $15.3M loss ($16.18/share) in Q | May 21, 2026 |
| IMMX | PRESS-RELEASE | bullish | 8/10 | Immix Biopharma announced that all four MRD-negative relapsed/refractory AL Amyloidosis patients from ASH 2025 have conv | May 21, 2026 |
| NBTX | PRESS-RELEASE | bearish | 6/10 | Nanobiotix has temporarily halted trading on Euronext Paris to finalize allocations and announce pricing for its previou | May 21, 2026 |
| RLAY | PRESS-RELEASE | bearish | 7/10 | Relay Therapeutics priced a $275M underwritten public offering of 22.9M shares at $12.00/share, representing approximate | May 20, 2026 |
| NBTX | PRESS-RELEASE | bearish | 5/10 | Nanobiotix launched a ~€75M (~$87M) global follow-on offering of ADSs and ordinary shares, plus pre-funded warrants. The | May 20, 2026 |
| DYN | PRESS-RELEASE | neutral | 2/10 | Dyne Therapeutics granted inducement equity awards to 17 newly hired employees, consisting of stock options for 296,500 | May 20, 2026 |
| VVOS | PRESS-RELEASE | mixed | 5/10 | Vivos Therapeutics reported Q1 2026 revenue of $5.14M (+70% YoY, 19.6% above consensus) but EPS of -$0.52 missed estimat | May 20, 2026 |
| LGVN | PRESS-RELEASE | neutral | 4/10 | Longeveron issued a CEO letter detailing a strategic repositioning toward a capital-light, partnership-focused model, wi | May 20, 2026 |
| ELDN | PRESS-RELEASE | neutral | 3/10 | Eledon Pharmaceuticals will present new clinical data from its tegoprubart Phase 2 BESTOW trial and extension study at t | May 20, 2026 |
| EQ | PRESS-RELEASE | neutral | 3/10 | Equillium announced a virtual investor event on May 27, 2026, to present new preclinical data on AhR modulators and the | May 20, 2026 |
| AIM | PRESS-RELEASE | bearish | 7/10 | AIM ImmunoTech announced a heavily dilutive registered direct offering of 7,519,351 shares at $0.325/share, raising ~$2. | May 20, 2026 |
| INKT | PRESS-RELEASE | neutral | 4/10 | MiNK Therapeutics presented a single-case report at ATS 2026 showing that sequential immunotherapy with Anktiva (N-803) | May 20, 2026 |
| PHAT | PRESS-RELEASE | neutral | 3/10 | Phathom Pharmaceuticals announced the presentation of 31 vonoprazan-related abstracts at DDW 2026, including a Phathom-s | May 20, 2026 |
| DYN | PRESS-RELEASE | bullish | 7/10 | Dyne Therapeutics initiated the Phase 3 FORZETTO trial of z-rostudirsen (DYNE-251) in Duchenne muscular dystrophy patien | May 20, 2026 |
| QUCY | PRESS-RELEASE | neutral | 4/10 | Quantum Cyber filed a provisional patent application for its SCOUT-AX6 GUARDIAN, an amphibious autonomous ground vehicle | May 20, 2026 |
| ROIV | PRESS-RELEASE | mixed | 7/10 | Roivant Sciences reported Q4 FY2026 GAAP EPS of $0.43 (including a $770M litigation settlement gain) vs consensus of -$0 | May 20, 2026 |
| IMVT | PRESS-RELEASE | bullish | 7/10 | Immunovant reported Q4 FY2026 net loss of $0.73/share, wider than prior year's $0.64 loss, driven by increased R&D spend | May 20, 2026 |
| PCRX | PRESS-RELEASE | mixed | 7/10 | Pacira BioSciences issued a press release urging stockholders to vote for its board nominees at the June 9 annual meetin | May 20, 2026 |
| BLTE | PRESS-RELEASE | mixed | 6/10 | Belite Bio reported Q1 2026 GAAP EPS of -$0.68, missing the -$0.64 consensus by 6.3%, with net loss widening to $26.9M f | May 20, 2026 |
| AURA | PRESS-RELEASE | neutral | 3/10 | Aura Biosciences granted inducement equity awards to new CEO Natalie Holles, consisting of stock options, RSUs, and perf | May 19, 2026 |
| ARTV | PRESS-RELEASE | bullish | 8/10 | Artiva Biotherapeutics announced five data presentations at the EULAR 2026 Congress (June 3-6, 2026) for its AlloNK (AB- | May 19, 2026 |
| RLAY | PRESS-RELEASE | bearish | 7/10 | Relay Therapeutics announced a $175 million underwritten public offering of common stock, with an additional 15% option | May 19, 2026 |
| ACHV | PRESS-RELEASE | bullish | 7/10 | Achieve Life Sciences presented comprehensive long-term safety data from the ORCA-OL study at ATS 2026, showing cytisini | May 19, 2026 |
| EDSA | PRESS-RELEASE | bullish | 6/10 | Edesa Biotech announced an oral presentation of Phase 3 data for paridiprubart in acute kidney injury at the ERA Congres | May 19, 2026 |
| PPCB | PRESS-RELEASE | neutral | 6/10 | Propanc Biopharma engaged a European CDMO for GMP manufacturing of its lead asset PRP, a proenzyme therapy for solid tum | May 19, 2026 |
| RNXT | PRESS-RELEASE | neutral | 3/10 | RenovoRx announced management participation in an AGP healthcare showcase and highlighted record Q1 2026 RenovoCath reve | May 19, 2026 |
| ONCO | PRESS-RELEASE | bearish | 5/10 | Onconetix announces a 1-for-10 reverse stock split effective May 21, 2026, to regain compliance with Nasdaq's $1 minimum | May 19, 2026 |
| ARTV | PRESS-RELEASE | neutral | 4/10 | Artiva Biotherapeutics appointed Diego Miralles, M.D., as President and Head of R&D. Dr. Miralles brings >20 years of dr | May 19, 2026 |
| PSTV | PRESS-RELEASE | neutral | 4/10 | Plus Therapeutics announced a strategic partnership with Ephemeral Technologies, an AI firm founded by former Palantir h | May 19, 2026 |
| ZBIO | PRESS-RELEASE | bullish | 7/10 | Zenas BioPharma announced that the Phase 3 INDIGO trial of obexelimab in IgG4-Related Disease met its primary endpoint a | May 19, 2026 |